How do you approach adjuvant therapy to minimize cardiotoxicity in early stage node negative HER2+ HR+ breast cancer with history of chest wall radiation and previous cardiotoxic agents for Hodgkin Lymphoma?

The recommended adjuvant treatment approach for a middle-aged patient with a history of mantle cell radiation for Hodgkin lymphoma and early-stage node-negative bilateral HER2+ HR+ breast cancer, while minimizing cardio toxicity, involves a multidisciplinary approach.

Given the patient's history of...